KR20150008082A - 수정된 항체 영역 및 그의 용도 - Google Patents

수정된 항체 영역 및 그의 용도 Download PDF

Info

Publication number
KR20150008082A
KR20150008082A KR1020147030719A KR20147030719A KR20150008082A KR 20150008082 A KR20150008082 A KR 20150008082A KR 1020147030719 A KR1020147030719 A KR 1020147030719A KR 20147030719 A KR20147030719 A KR 20147030719A KR 20150008082 A KR20150008082 A KR 20150008082A
Authority
KR
South Korea
Prior art keywords
region
modified
antibody
numbering
positions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020147030719A
Other languages
English (en)
Korean (ko)
Inventor
거하드 프레이
제이 엠. 쇼트
화이 웬 창
Original Assignee
바이오아트라, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오아트라, 엘엘씨 filed Critical 바이오아트라, 엘엘씨
Publication of KR20150008082A publication Critical patent/KR20150008082A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020147030719A 2012-04-27 2013-04-26 수정된 항체 영역 및 그의 용도 Ceased KR20150008082A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261639729P 2012-04-27 2012-04-27
US61/639,729 2012-04-27
PCT/US2013/038538 WO2013163630A1 (en) 2012-04-27 2013-04-26 Modified antibody regions and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207009090A Division KR20200037434A (ko) 2012-04-27 2013-04-26 수정된 항체 영역 및 그의 용도

Publications (1)

Publication Number Publication Date
KR20150008082A true KR20150008082A (ko) 2015-01-21

Family

ID=49483948

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020147030719A Ceased KR20150008082A (ko) 2012-04-27 2013-04-26 수정된 항체 영역 및 그의 용도
KR1020207009090A Ceased KR20200037434A (ko) 2012-04-27 2013-04-26 수정된 항체 영역 및 그의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207009090A Ceased KR20200037434A (ko) 2012-04-27 2013-04-26 수정된 항체 영역 및 그의 용도

Country Status (13)

Country Link
US (2) US20150065690A1 (OSRAM)
EP (2) EP3470433B1 (OSRAM)
JP (1) JP6470170B2 (OSRAM)
KR (2) KR20150008082A (OSRAM)
CN (1) CN104428317B (OSRAM)
AU (3) AU2013251309B2 (OSRAM)
BR (1) BR112014026740B1 (OSRAM)
CA (1) CA2871807C (OSRAM)
HK (1) HK1207654A1 (OSRAM)
IN (1) IN2014DN08721A (OSRAM)
MX (2) MX360368B (OSRAM)
RU (1) RU2014147741A (OSRAM)
WO (1) WO2013163630A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10329556B2 (en) 2014-05-13 2019-06-25 Bioatla, Llc Conditionally active biological proteins
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
BR112018011781A2 (en) 2015-12-14 2018-12-04 Macrogenics, Inc. bispecific molecule having one or more epitope binding sites capable of immunospecific binding to (one) pd-1 epitope (s) and one or more epitope binding sites capable of immunospecific binding to (one) epitope (s) -4, and pharmaceutical composition
JP7155008B2 (ja) * 2016-03-14 2022-10-18 ウニヴァーシテテット イ オスロ 変化されたＦｃＲｎを有する改変された免疫グロブリン
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
JP7445995B2 (ja) * 2018-10-31 2024-03-08 バイオアトラ インコーポレイテッド 抗ｃｔｌａ４抗体、抗体断片、それらの免疫コンジュゲートおよびそれらの使用
WO2020142625A2 (en) * 2019-01-03 2020-07-09 Invetx Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use
SG11202109172TA (en) 2019-03-08 2021-09-29 Obsidian Therapeutics Inc Human carbonic anhydrase 2 compositions and methods for tunable regulation
US20240124889A1 (en) 2019-05-07 2024-04-18 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
US20220308072A1 (en) 2019-08-12 2022-09-29 Voyager Therapeutics, Inc. High-sensitivity immunoassay for the detection of frataxin in biofluids
WO2021040736A1 (en) 2019-08-30 2021-03-04 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
US20220348937A1 (en) 2019-09-06 2022-11-03 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
MX2022012076A (es) * 2020-05-21 2022-10-13 Zydus Lifesciences Ltd Variante del fc y preparacion de la misma.
US20210363512A1 (en) 2020-05-22 2021-11-25 Formycon Ag ACE2 fusion proteins and uses thereof
EP4204091A2 (en) 2020-10-29 2023-07-05 Formycon AG Ace2 fusion proteins and uses thereof
US20240139296A1 (en) 2021-03-03 2024-05-02 Formycon Ag Formulations of ace2 fc fusion proteins
WO2023094507A1 (en) 2021-11-24 2023-06-01 Formycon Ag Improved ace2 fusion proteins
WO2023094571A1 (en) 2021-11-25 2023-06-01 Formycon Ag Stabilization of ace2 fusion proteins
EP4386084A1 (en) 2022-12-14 2024-06-19 Formycon AG Improved ace2 fusion proteins

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1562972B1 (en) * 2002-10-15 2010-09-08 Facet Biotech Corporation ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AU2003280247A1 (en) 2002-11-05 2004-06-07 Affinium Pharmaceuticals, Inc. Essential novel bacterial polypeptides
WO2004063351A2 (en) * 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
JP2007531707A (ja) 2003-10-15 2007-11-08 ピーディーエル バイオファーマ， インコーポレイテッド ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変
EP1697415A1 (en) * 2003-11-12 2006-09-06 Biogen Idec MA Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
MX2007000404A (es) * 2004-07-12 2008-03-04 Macrogenics Inc Identificacion de ingenieria de anticuerpos con regiones de fc variante y metodos para usar las mismas.
EP1919950A1 (en) * 2004-07-15 2008-05-14 Xencor, Inc. Optimized fc variants
CA2587766A1 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
EP2325207B1 (en) * 2004-11-12 2017-03-15 Xencor, Inc. FC variants with altered binding to FCRN
WO2006105062A2 (en) * 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
ES2579602T3 (es) * 2005-08-10 2016-08-12 Macrogenics, Inc. Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de uso de estos
CN101331223A (zh) * 2005-10-14 2008-12-24 米迪缪尼有限公司 细胞展示抗体文库
BR122021010656B1 (pt) * 2007-12-26 2022-07-19 Xencor, Inc Anticorpo anti-tnf e composição farmacêutica
EP2282770B1 (en) * 2008-06-04 2018-03-07 MacroGenics, Inc. Antibodies with altered binding to fcrn and methods of using same
US20120100140A1 (en) 2009-01-23 2012-04-26 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
MY199658A (en) 2009-06-26 2023-11-14 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
AU2011285852B2 (en) * 2010-08-03 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US8483058B2 (en) 2010-08-17 2013-07-09 Qualcomm Incorporated Systems and methods for traffic policing
WO2013010927A1 (en) 2011-07-15 2013-01-24 Basell Poliolefine Italia S.R.L. Polyolefin strap comprising a random copolymer of propylene with 1-hexene
SG11201401102VA (en) * 2011-09-30 2014-09-26 Chugai Pharmaceutical Co Ltd Ion concentration-dependent binding molecule library
AU2012366290A1 (en) * 2012-01-19 2014-08-07 Therapeutic Proteins International, LLC Stabilization of the anti-CD20 antibody Rituximab

Also Published As

Publication number Publication date
MX382840B (es) 2025-03-13
US20180186863A1 (en) 2018-07-05
EP3470433A1 (en) 2019-04-17
RU2014147741A (ru) 2016-06-20
AU2013251309A1 (en) 2014-10-30
US10954288B2 (en) 2021-03-23
BR112014026740B1 (pt) 2022-10-04
AU2019202229A1 (en) 2019-04-18
BR112014026740A8 (pt) 2021-06-15
KR20200037434A (ko) 2020-04-08
CA2871807A1 (en) 2013-10-31
JP2015515497A (ja) 2015-05-28
MX360368B (es) 2018-10-29
EP2841458A1 (en) 2015-03-04
IN2014DN08721A (OSRAM) 2015-05-22
EP2841458A4 (en) 2015-09-16
AU2013251309B2 (en) 2017-06-22
AU2017225111A1 (en) 2017-09-28
MX2014012978A (es) 2015-02-05
HK1207654A1 (en) 2016-02-05
WO2013163630A1 (en) 2013-10-31
AU2017225111B2 (en) 2019-01-03
CN104428317A (zh) 2015-03-18
CN104428317B (zh) 2018-08-28
BR112014026740A2 (pt) 2017-06-27
AU2019202229B2 (en) 2021-02-11
JP6470170B2 (ja) 2019-02-13
US20150065690A1 (en) 2015-03-05
EP3470433B1 (en) 2025-12-03
CA2871807C (en) 2022-10-04

Similar Documents

Publication Publication Date Title
KR20150008082A (ko) 수정된 항체 영역 및 그의 용도
US9580496B2 (en) Therapeutic canine immunoglobulins and methods of using same
AU2012252156B2 (en) Therapeutic canine immunoglobulins and methods of using the same
JP6371758B2 (ja) 抗ブドウ球菌抗体、その製造方法並びにその使用
CN103906764A (zh) 犬源化抗体及其制备方法
ES2869890T3 (es) Proteínas de unión que tienen cadenas ligeras atadas
JP7127859B2 (ja) キメラタンパク質を用いたアレルギー疾患の治療
HK40009281A (en) Modified antibody regions and uses thereof
JPH06503956A (ja) 腫瘍細胞に対する標的決定ＩｇＥエフェクター細胞
JP6903083B2 (ja) 汎用性抗体フレームワークを用いたイエウサギ抗体のヒト化
HK1195572B (en) Therapeutic canine immunoglobulins and methods of using the same

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141031

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180424

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190718

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20191227

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190718

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200330

PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20191227

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20190920

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20180424

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20200501

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200330

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20191227

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190920

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20190718

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180424

X601 Decision of rejection after re-examination